Selected-GenAtlas references	SOURCE	GeneCards	NCBI Gene	Swiss-Prot	Ensembl
	HGNC	UniGene	Nucleotide	OMIM	UCSC

Home Page

FLASH GENE

Symbol

KLK10

contributors: mct - updated : 08-04-2020

HGNC name	kallikrein-related peptidase 10
HGNC id	6358

FLASH GENE DNA RNA EXPRESSION PROTEIN DISORDER ANIMAL & CELL MODELS

DNA

TYPE	functioning gene
SPECIAL FEATURE	component of a cluster
text	tightly clustered multigene family on chromosome 19q13.4
STRUCTURE	7.43 kb     6 Exon(s)

10 Kb 5' upstream gene genomic sequence study

MAPPING

cloned

Y

linked

N

status

confirmed

regionally located

clustered with kallikrein gene family

RNA

TRANSCRIPTS	type	messenger

identification nb exons type bp product Protein kDa AA specific expression Year Pubmed NM_002776 6 splicing 3123 NP_002767 30.1 276 - 2017 2841983 NM_145888 6 splicing 2985 NP_665895 30.1 276 - 2017 2841983 NM_001077500 6 - 3024 NP_001070968 - 276 - 2017 2841983

EXPRESSION

Type

widely

expressed in	(based on citations)
organ(s)	System Organ level 1 Organ level 2 Organ level 3 Organ level 4 Level Pubmed Species Stage Rna symbol Lymphoid/Immune tonsils       highly Homo sapiens Reproductive female system breast     highly   female system ovary     highly   male system prostate     highly Respiratory respiratory tract larynx     highly Urinary kidney tubule     highly

cells

System Cell Pubmed Species Stage Rna symbol Lymphoid/Immune B cell Homo sapiens

cell lineage
cell lines
fluid/secretion	secreted

at STAGE

PROTEIN

PHYSICAL PROPERTIES

STRUCTURE

motifs/domains

HOMOLOGY

interspecies

homolog to C.elegans T27E9.4b

Homologene

FAMILY	kallikrein family
	peptidase S1 family

CATEGORY

enzyme , tumor suppressor

SUBCELLULAR LOCALIZATION	extracellular
	intracellular
	intracellular,cytoplasm,cytosolic,granule

basic FUNCTION	tumor suppressor role in breast and prostate cancer
	KLK9 and KLK10, once activated, are unlikely to participate in further pro-KLK activation pathways, although similar to KLK1 they may activate other bioactive peptides
	estrogen-sensitive kallikreins with KLK14, and KLK11, all synergistically enhanced and upregulated by androgens in breast cancer cells via a membrane bound androgen receptor
	having the ability to inhibit anchorage-independent growth in hepatoma cells
	lower KLK10 levels in salivary gland pleomorphic adenoma, suggesting aberrant expression in a tumour that develops primarily from myoepithelial cells
	may function as a tumour suppressor by repressing proliferation, enhancing apoptosis and decreasing glucose metabolism in PC3 prostate cancer cells

CELLULAR PROCESS

protein, degradation

PHYSIOLOGICAL PROCESS

PATHWAY

metabolism

signaling

a component

INTERACTION

DNA

RNA

small molecule

protein	kinin B1 receptor agonist induces secretion of KLK1, KLK6, KLK10, KLK13 and KLK14 into the medium nof neutrophils
	LMNA and EMD modulate KLK10, SMAD2 and BCL2L12 expression levels as well as the spatial positions of gene loci in the interphase nucleus

cell & other

REGULATION

Other

differentially regulated through distinct epigenetic mechanisms in HBV- and HCV-related hepatocellular carcinoma

ASSOCIATED DISORDERS

corresponding disease(s)

Other morbid association(s)

Type Gene Modification Chromosome rearrangement Protein expression Protein Function tumoral     --over   in ovarian, colorectal and gastric cancer and higher expression of KLK10 closely correlates with advanced disease stage, which predicts a poorer prognosis tumoral     --low   in breast cancer (in progression), and in testicular cancer, in cervical cancer, prostate cancer and acute lymphocytic leukemia tumoral     --over   in oral squamous cell carcinoma and may be implicated in malignant progression tumoral     --low   in hepatocellular carcinoma by hypermethylation, significantly associated with cirrhosis and HCV infection as well as inversely associated with HBV infection constitutional     --over   significantly increased in Alzheimer disease tumoral     --over   increased KLK10 and KLK11 protein expression is associated with favorable prognosis in advanced high-grade serous ovarian cancer

Susceptibility

Variant & Polymorphism

Candidate gene
Marker	potential biomarker in colon adenocarcinoma
	promising biomarker for diagnosis in Pancreatic Ductal Adenocarcinoma (PADC)
	KLK6 and KLK10 may be useful markers in gastroesophageal junction tumors
Therapy target
	System Type Disorder Pubmed cancer endocrine pancreas potential target for therapy in Pancreatic Ductal Adenocarcinoma (PADC) cancer digestive oesophagus potential therapeutic targets in gastroesophageal junction tumors

ANIMAL & CELL MODELS